Inhibikase Therapeutics, Inc. (IKT)

NCM – Real Time Price. Currency in USD

2.42

-0.03 (-1.22%)

Market open: Aug 12, 2026, 10:52 AM EDT

2.49

+0.04 (1.63%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.

Videos

No Data

There is no data to display

Press releases

11.08.2026

Inhibikase Therapeutics, Inc. (IKT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Videos

No Data

Press releases

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Videos

No Data

Press releases

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Search stocks

Inhibikase Therapeutics, Inc. (IKT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Videos

No Data

Press releases

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Videos

No Data

Press releases

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity